

JUBILANT PHARMA LIMITED
(Company Registration No. 200506887H)
(Incorporated in the Republic of Singapore)
Registered office: 80 Robinson Road, #02-00, Singapore 068898

March 8, 2019

Singapore Exchange Securities Trading Limited

11 North Buona Vista Drive #06-07
The Metropolis Tower 2
Singapore 138589


Dear Sirs,

We enclose a communication pertaining to issue of Warning Letter by USFDA for manufacturing facility at Roorkee, India.

This is for your kind information and records.

Thanking you,

Yours faithfully,
For Jubilant Pharma Limited



Arun Kumar Sharma
Chief Financial Officer

Encl.: as above

**Jubilant Pharma Ltd.**

6 Temasek Boulevard, #20-06
Suntec City Tower Four, Singapore 038986
Tel.: +65 6235 4129
www.jubilantpharma.com

USFDA issues Warning Letter for Roorkee facility, India

Noida (UP), India, Friday, March 8, 2019

Jubilant Pharma Limited (JPL), a material wholly owned subsidiary of Jubilant Life Sciences Ltd (JLL) India, has announced that with reference to the USFDA inspection conducted at the manufacturing facility at Roorkee, India of solid dosage formulations during August 2018 and the subsequent intimation from the agency of classifying the facility as "Official Action Indicated" (OAI) in December 2018, the agency has further issued a Warning letter for the Roorkee facility. The USFDA may withhold approval of any new applications or supplements till the company addresses all issues raised by the agency. However, we believe that the existing manufacturing and sale of products from this facility will not be impacted. US revenues from the facility is about 6% of the total revenues of the company.

The company is committed to implementing the necessary corrective actions required to address USFDA concerns and is in the process of providing a thorough and comprehensive response to the USFDA within 15 working days.

About Jubilant Pharma Limited

Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly owned subsidiary of Jubilant Life Sciences Limited, is an integrated global Pharmaceutical company engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectibles and Non-sterile products through 6 USFDA approved manufacturing facilities in the US, Canada and India and a network of over 50 radio-pharmacies in the US. The Company has a team of over 4,300 multicultural people across the globe and is committed to deliver value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally.

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. For detailed disclaimer in case of Jubilant Pharma Limited, please visit <http://www.jubilantpharma.com/fullpage.aspx?mpgid=1147&pgid=1147>